Registration Dossier

Toxicological information

Carcinogenicity

Currently viewing:

Administrative data

Description of key information

alpha-Terpineol and beta-terpineol injected intraperitoneally to mice were not found to be carcinogenic.

Key value for chemical safety assessment

Carcinogenicity: via oral route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

Female mice were given intraperitoneal injections of alpha-terpineol or beta-terpineol at 1900 and 9600 mg/kg bw in tricaprylin, 3 times a week for a total of 24 doses. Animals were then observed for mortality and bodyweights for 24 weeks after first injection and were all macroscopically necropsied after death or sacrifice. No dose-related increase was observed in tumor formation.


Justification for selection of carcinogenicity via oral route endpoint:
Further testing is not required under Annex X, column 2, section 8.9.1. Terpineol multiconstituent is not classified as a mutagen and there is no evidence from the repeated dose studies that terpineol multiconstituent but also alpha- and beta-terpineol are able to induce hyperplasia or pre-neoplastic lesions. Therefore, no further study is deemed necessary.

Justification for classification or non-classification

Terpineol multiconstituent is not classified as a mutagen and there is no evidence from the repeated dose studies that terpineol multiconstituent but also alpha-terpineol and beta-terpineol are able to induce hyperplasia or pre-neoplastic lesions. Therefore, terpineol multiconstituent is not classified according to directive 67/548/EEC and CLP regulation (EC) No 1272/2008.